ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Icosavax Inc

Icosavax Inc (ICVX)

15.31
0.00
(0.00%)
Closed July 21 4:00PM
0.00
0.00
(0.00%)

Calls

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
2.500.000.000.000.000.000.00 %00-
5.000.000.000.000.000.000.00 %00-
7.500.000.000.000.000.000.00 %00-
10.000.000.000.000.000.000.00 %00-
12.500.000.000.000.000.000.00 %00-
15.000.000.000.000.000.000.00 %00-
17.500.000.000.000.000.000.00 %00-
20.000.000.000.000.000.000.00 %00-
22.500.000.000.000.000.000.00 %00-
25.000.000.000.000.000.000.00 %00-

Professional-Grade Tools, for Individual Investors.

Puts

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
2.500.000.000.000.000.000.00 %00-
5.000.000.000.000.000.000.00 %00-
7.500.000.000.000.000.000.00 %00-
10.000.000.000.000.000.000.00 %00-
12.500.000.000.000.000.000.00 %00-
15.000.000.000.000.000.000.00 %00-
17.500.000.000.000.000.000.00 %00-
20.000.000.000.000.000.000.00 %00-
22.500.000.000.000.000.000.00 %00-
25.000.000.000.000.000.000.00 %00-

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SERVServe Robotics Inc
$ 7.51
(185.55%)
262.73M
AUGXAugmedix Inc
$ 2.27
(147.71%)
21.87M
XCURExicure Inc
$ 0.5351
(76.02%)
14.02M
PSNLPersonalis Inc
$ 3.83
(56.33%)
22.76M
MDBHMDB Capital Holdings LLC
$ 10.675
(37.21%)
126.13k
SPWRSunPower Corporation
$ 0.6735
(-55.40%)
124.61M
HYZNHyzon Motors Inc
$ 0.149
(-47.54%)
23.63M
MEDSTRxADE Health Inc
$ 14.92
(-33.45%)
223.27k
SILOSilo Pharma Inc
$ 2.50
(-27.95%)
11.93M
KITTNauticus Robotics Inc
$ 0.0935
(-27.46%)
28.43M
SERVServe Robotics Inc
$ 7.51
(185.55%)
262.73M
NVDANVIDIA Corporation
$ 117.93
(-2.61%)
206.41M
SXTP60 Degrees Pharmaceuticals Inc
$ 0.2602
(5.77%)
202.14M
SQQQProShares UltraPro Short QQQ
$ 8.46
(2.79%)
184.21M
SPWRSunPower Corporation
$ 0.6735
(-55.40%)
119.98M

ICVX Discussion

View Posts
TheFinalCD TheFinalCD 7 months ago
AstraZeneca to Buy Icosavax for Up to $1.1 Bln

$ICVX
https://finance.yahoo.com/m/70b0bcc4-729d-378c-9f8c-27616ef35a3e/astrazeneca-to-buy-icosavax.html
👍️0
Jess070283 Jess070283 1 year ago
I keep adding. About to be unleashed soon.$$$
👍️0
Louman Louman 2 years ago
Shares getting locked up. RSV vaccine in the pipeline. Could it get FDA fast track?
👍️0
Jess070283 Jess070283 2 years ago
Squeeze!!!!
👍️0
makinezmoney makinezmoney 2 years ago
$ICVX: Jan 2023 $10 Calls were $0.20 yesterday.................


Just hit $4.40 !!!!!!!!!!!!!!!!


WOW................... a beautiful 22x bagger !!!!!!!!!!!!!!


Thank you


GO $ICVX
👍️0
makinezmoney makinezmoney 2 years ago
$ICVX: $13 baby................... people missing this


Oh welllllllllllllllllllllllll



Lets get to $25......... i know you can, like that MonkePox call I made in JULY


GO $ICVX
👍️0
makinezmoney makinezmoney 2 years ago
$ICVX: BOOMmmmmmmmmm .......... now 10.30

Whatta move since the initial call

Everyone missed the RSV news from a couple days ago

Icosavax Reports Positive Durability Data for VLP Vaccine Candidate IVX-121 Against RSV at Six-Month Timepoint
December 13 2022 - 04:05PM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today provided a six-month immunogenicity update from its Phase 1/1b trial of IVX-121 against Respiratory Syncytial Virus (RSV). These new data demonstrate a sustained neutralizing antibody (nAb) response against RSV, lasting for at least six months after a single administration of IVX-121.
“We are delighted to share the six-month immunogenicity data from our Phase 1/1b trial of IVX-121. The potential for long-lasting immune responses was part of our founding hypothesis and preclinical rationale for developing combination VLP vaccines, so it is exciting to see this supportive initial clinical data on durability from our platform,” said Adam Simpson, Chief Executive Officer of Icosavax. “We continue to believe that there is a need for better vaccines, in particular the potential for combination respiratory vaccines with longer-lasting protection and low reactogenicity.”

IVX-121 (RSV) Phase 1/1b six-month immunogenicity update

IVX-121 continued to be generally well-tolerated with no safety concerns observed in this six-month follow up and no vaccine related serious adverse events (SAEs).

Data shown and described below illustrate the ongoing neutralizing antibody responses to a single administration of IVX-121 at three dosage levels (25, 75, 250 µg), in the groups without adjuvant. Samples were taken at baseline, day 28, and day 180, with neutralizing antibodies measured in international units (IU/mL) using the WHO international reference standard.


Lets go $TMNA next


GO $ICVX
👍️ 1
makinezmoney makinezmoney 2 years ago
$ICVX: DAMMmmmmnnnnnn now 7.80


MASSSIVE mmove into the close.


Very impressive


GO $ICVX
👍️0
makinezmoney makinezmoney 2 years ago
$ICVX: Helluva move today........ now 6.90


Evercore ISI has a $18 target on it.......... bounced off that bottom, some squeezing going on.

Currently trading at 5.91 Cash/share


Hmmmmmmmmmmmmmm.............. interesting move.

Beaten down HARDDDDDDDDDddd this year


WOW


GO $ICVX
👍️0

Your Recent History

Delayed Upgrade Clock